Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen’s Q1 Revenue Soars, Net Loss Remains Flat

NEW YORK (GenomeWeb News) - Nanogen yesterday said first-quarter revenues increased 120 percent as R&D spending ticked up 4 percent and its net loss decreased by just over one percent.
 
Total receipts for the three months ended March 31, 2007, increased to $9.7 million from $4.4 million year over year.
 
The company said product-related revenue nearly tripled to $6.1 million from $2.1 million, and income from licensing and royalties dipped 33 percent to $1.2 million from $1.8 million. Revenue from contracts and grants rose more than five-and-a-half-fold to $2.3 million from $416,000.
 
Nanogen CEO Howard Birndorf said in a statement that the revenue growth reflects the company's strategy of expanding its product line and the increasing acceptance of its products in the personalized medicine market.
 
R&D spending rose to $6.5 million from $6.3 million year over year.
 
The company said its net loss declined to $11.8 million from $12 million in the year-ago period.
 
Nanogen had around $8.81 million in cash and equivalents and $12.4 million in short-term investments as of March 31.
 
The company said it expects revenue to grow more than 50 percent for the full year 2007 compared with 2006, when it posted $26.9 million in revenue.  

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.